Prominent Independent Proxy Advisory Firm ISS Supports NovaBay Pharmaceuticals' Proposals to Authorize the Sale of its Avenova Brand [Yahoo! Finance]
NovaBay Pharmaceuticals, Inc. (NBY)
NASDAQ:AMEX Investor Relations:
novabay.com/investors
Company Research
Source: Yahoo! Finance
EMERYVILLE, Calif., November 15, 2024 BUSINESS WIRE NovaBay ® Pharmaceuticals, Inc. (NYSE American: NBY) ("NovaBay" or the "Company") announces that the largest institutional advisory firm, Institutional Shareholder Services (ISS), has recommended that NovaBay stockholders vote in favor of all of the Company's proxy proposals, specifically to authorize and approve the sale of its eyecare business (the "Asset Sale Proposal") and approve the voluntary liquidation and dissolution of the Company (the "Dissolution Proposal"). Proposal One (the Asset Sale Proposal) and Proposal Two (the Dissolution Proposal) are further described in the Definitive Proxy Statement , filed on October 16, 2024 (the "Special Meeting Proxy Statement"), as supplemented including by the Additional Definitive Proxy Soliciting Materials filed on November 6, 2024 and November 12, 2024 The NovaBay Board of Directors unanimously supports the Asset Sale Proposal seeking stockholder approval for the sale of substantia
Show less
Read more
Impact Snapshot
Event Time:
NBY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NBY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NBY alerts
High impacting NovaBay Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
NBY
News
- NovaBay Pharmaceuticals, Inc. (NYSE: NBY) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Prominent Independent Proxy Advisory Firm ISS Supports NovaBay Pharmaceuticals’ Proposals to Authorize the Sale of its Avenova BrandBusiness Wire
- NovaBay Pharmaceuticals, Inc. (NYSE: NBY) had its price target lowered by analysts at Ascendiant Capital Markets from $8.00 to $0.85. They now have a "buy" rating on the stock.MarketBeat
- NovaBay Pharmaceuticals, Inc. (NYSE: NBY) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- NovaBay Pharmaceuticals Reports Third Quarter 2024 Financial ResultsBusiness Wire
NBY
Analyst Actions
- 11/11/24 - Ascendiant Capital
NBY
Sec Filings
- 11/15/24 - Form DEFA14A
- 11/13/24 - Form DEFA14A
- 11/12/24 - Form DEFA14A
- NBY's page on the SEC website